Prostate Cancer Highlights from ASCO GU 2022

Episode 1 • March 08, 2022 • 00:38:59
Prostate Cancer Highlights from ASCO GU 2022
COR2ED Medical Education
Prostate Cancer Highlights from ASCO GU 2022

Mar 08 2022 | 00:38:59

/

Show Notes

COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Prostate Cancer Highlights from ASCO GU 2022’ in this GU CONNECT podcast.

In this podcast, the experts review data from a number of key plenary sessions from ASCO GU 2022 and discuss potential implications for clinical practice. The ARASENS trial is covered first which looked at triplet therapy in the form of ADT plus docetaxel and darolutamide in patients with metastatic castration sensitive prostate cancer (mCSPC). Discussion then moves to two trials investigating the combination of abiraterone acetate with PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) patients with and without homologous recombination repair (HRR) mutations: the PROpel trial with olaparib and the MAGNITUDE trial with rucaparib. 

Neal and Alicia also discuss a fascinating presentation by Dr. Daniel Spratt which looked at digitising histopathology slides and using Artificial Intelligence (AI) to inform on the likelihood of disease progression and whether or not patients needed androgen deprivation therapy (ADT)

Finally, Alicia discusses a number of posters which she felt made an impact, including one on PSA responses in the TITAN and SPARTAN trials and a secondary analysis from the VISION trial looking at treatment related adverse events, amongst others. 

Other Episodes

Episode

December 04, 2023 • 00:33:58
Episode Cover

Diagnosis and management of short stature patients

Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges...

Listen

Episode 1

August 17, 2022 • 00:29:42
Episode Cover

Role of immunotherapy beyond advanced HCC

COR2ED Medical Education: In this podcast, liver cancer experts Prof. Amit Singal and Assoc. Prof Neil Mehta discuss recent advances in systemic and locoregional...

Listen

Episode 3

March 16, 2022 • 00:19:56
Episode Cover

High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

COR2ED Medical Education: In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin...

Listen